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The combination of vancomycin or daptomycin plus ceftaroline has showed synergistic results in vitro. This study
aimed to investigate in vitro synergy of vancomycin or daptomycin plus ceftaroline for seven patients with dap-
tomycin non-susceptible Staphylococcus aureus (SA) bacteremia
Thirteen isolates from seven patients were evaluated: two methicillin-susceptible and five methicillin-resistant
SA infections. All patientswere treatedwith daptomycin and becamenon-susceptible (minimum inhibitory concen-
tration (MIC) N1 μg/mL) with therapy or had resistant strains initially. Time kill experiments were completed with
0.25×MIC, 0.5 ×MIC, and 0.75×MIC concentrations. No synergywas seen at 0.25×MIC. Synergywas observed for
4 isolates with vancomycin plus ceftaroline and with daptomycin plus ceftaroline for 2 isolates at 0.5 × MIC.
These results are in accordancewith literature that supports synergistic combinations of daptomycin or vancomycin
with ceftaroline for SA bacteremia. Daptomycin non-susceptible SA bacteremia presents a treatment challenge.
© 2020 Elsevier Inc. All rights reserved.
Staphylococcus aureus (SA) is a virulent organism with the ability
to develop resistance against many different antimicrobial classes
(Lowy, 2003) forwhich the Centers for Diseases Control has nameda se-
rious antibiotic-resistant threat. For patientswith persistent bacteremia,
deep-seated infections, or resistant isolates, the management of these
infections can be challenging. Current best practice recommendations
suggest combination therapy with daptomycin and another anti-
staphylococcal agent if methicillin-resistant SA (MRSA) bacteremia
persists or vancomycin therapy fails (Liu et al., 2011).
Many antimicrobial combinations utilizing different mechanisms of
action have been studied both in vitro and in vivo in hopes to elucidate
a regimen able to effectively treat these patients (Nguyen & Graber,
2010; Steigbigel et al., 1975). The addition of a beta-lactam to daptomy-
cin therapy has been shown to increase daptomycin killing by enhanc-
ing daptomycin binding leading to rapid bacteremia clearance (Dhand
et al., 2011). Additionally, the combination of vancomycin or daptomy-
cin plus ceftaroline has showed promising in vitro synergistic results.
Rose and colleagues reported synergistic combinations of daptomycin
or vancomycin with ceftaroline that resulted in significantly lower
daptomycin MICs compared to monotherapy (Rose et al., 2012). Fur-
thermore, Rybak and colleagues demonstrated in vitro improved killing
with the combination of these antimicrobials versus either agent alone,
although it is important to note that synergy was seen in sixty-seven
percent of strains tested (Werth et al., 2014).
However, we lack clear treatment guidelines for treatment of dapto-
mycin non-susceptible SA bacteremias. More in vitro and in vivo studies
need to be completed to evaluate the synergistic relationship of com-
monly used anti-MRSA agents. We present our in vitro synergy results
with combinations of vancomycin or daptomycin plus ceftaroline for
seven patients with daptomycin non-susceptible SA bacteremia.
1. Materials and methods
The studywas performed at a five-hospital health system, Henry Ford
Health System, in Detroit, Michigan. Blood isolates initial identification
and sensitivities were performed in the clinical microbiology laboratory
as part of routine patient care. Additional MIC and synergy testing were
completed within the infectious diseases research laboratory. We in-
cluded all of the daptomycin non-susceptible SA strains isolated from
2015–2017. Daptomycin non-susceptibility was defined as a MIC N1 μg/
ml. MICs were determined by manual broth microdilution (BMD) using
Clinical and Laboratory Standards Institute standards (CLSI, 2015).
Blood isolates from 7 patients with SA bacteremia were evaluated:
two with methicillin-susceptible and five with MRSA infections. All
the patients initially had non-susceptible strains or were treated with
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daptomycin and became non-susceptible during therapy. Thirteen
isolates were obtained; six patients had first and last isolates evaluated,
and one patient had one isolate obtained, as he expired before another
isolate could be acquired. Two of the first isolates and all of the last
isolates were daptomycin non-susceptible with MICs greater than 1
μg/mL.We also performed synergies using quality control strains, Staph-
ylococcus aureus ATCC 29213 and Klebsiella pneumoniae ATCC 700603.
Cation-adjusted Mueller-Hinton II broth (CA-MHB; BBL, Sparks, MD)
was used for all BMD and synergy time kill experiments (TKE) and sup-
plemented with CaCl2 for a final concentration of 50 mg/L for all dapto-
mycin testing. Combinations of daptomycin plus ceftaroline and
vancomycin plus ceftaroline were tested for synergy, and all TKE were
completed in duplicate using sub-inhibitory 0.25 × MIC, 0.5 × MIC,
and 0.75 × MIC concentrations. If an isolate showed synergy at 0.5 ×
MIC, 0.75 × MIC TKE were not completed. Methods of synergy testing
were completed as previously described (NCCLS, 1999). The original
bacterial inoculum was approximately 5 × 105 CFU/mL. Testing was
performed in four tubes (A-D) with 10ml total volumes; Tubes A and
B as vancomycin/daptomycin and ceftaroline alone, tube C as the com-
bination of vancomycin/ceftaroline or daptomycin/ceftaroline, and
tube D as a growth control. Synergy was defined as ≥2 log10 decrease
in CFU/mL between the combination and its most active constituent
after 24 h (Eliopoulos & Moellering, 1991).
Pulsed-field gel electrophoresis (PFGE) was performed on each iso-
late to evaluate strain typing. Genomic DNAwas prepared using amod-
ified version of a previously described method (McDougal et al., 2003)
andwas digestedwith SmaI restriction endonuclease. A CHEF-DR III sys-
tem (Bio-Rad, Hercules, CA) was used to perform all PFGE. Data for all
SA isolates were entered into a Gel Doc XR+Gel Documentation System
(Bio-Rad, Hercules, CA) database and PFGE patterns were compared
using BioNumerics software (Applied Maths, St-Martens-Latem,
Belgium). Isolates were placed in the same PFGE group if SmaI restric-
tion patterns were ≥80% similarity using the Dice coefficient. Isolates
were classified into PFGE groups according to the US Centers for Disease
Control and Prevention (CDC) classification system (McDougal et al.,
2003). Whole genome sequencing (WGS) was performed for DNA from
13 isolates and two quality control strains;methicillin-sensitive Staphylo-
coccus aureus ATCC 29213 and methicillin-resistant control strain FoxR
was extracted and purified using the DNeasy® Blood and Tissue Kit pro-
tocol (Qiagen).WGSwasperformedby theAppliedGenomics Technology
Center in Detroit, MI using Nextera XT DNA Library Prep Kitgenerated li-
braries run as 300 bp paired-end reads on a MiSeq. The following genetic
loci previously implicated in daptomycin non-susceptibility were investi-
gated usingWGS: vraR (Iwata et al., 2017), vraS (Iwata et al., 2017),mprF
(Tran et al., 2015), dltA (Tran et al., 2015), cls2 (Tran et al., 2015), and
gdpD (Arias et al., 2011).
2. Results
In the quality control strains, synergy was observed using SA 29213
in both vancomycin/ceftaroline and daptomycin/ceftaroline combina-
tions, while, as predicted, none were seen with KP700603 in both com-
binations. No synergy was noted for any isolate with either vancomycin
or daptomycin plus ceftaroline at 0.25 × MIC. At 0.5 × MIC, synergy of
vancomycin and ceftaroline was observed in 4 patients. For the 3
patients that synergy was not observed, 0.75 ×MIC became synergistic,
but only in the last isolates obtained from the patient. Only two patients
had synergy with daptomycin and ceftaroline at 0.5 × MIC. Again, this
was only observed in the last isolates obtained from the patients. By in-
creasing the concentration to 0.75 × MIC, all but one patient had syn-
ergy observed with daptomycin and ceftaroline. See Table 1 for first
and last isolate MICs. See Fig. 1a–g for 24-h TKE for each patient. Please
note 4-hour TKE were not able to be completed in the 0.75 × MIC
daptomycin and ceftaroline studies for patients 2 and 3.
PFGE was used to assess if there were intrinsic changes, such as the
introduction of a new strain or modification of the existing strain, con-
tributing to the evolution of daptomycin non-susceptibility in 13 SA iso-
lates obtained from seven patients (see Fig. 2). Four of these isolates
were methicillin-susceptible and the remaining 9 were methicillin-
resistant. Table 2 demonstrates comparison of isolate strains with
established CDC SA strains (McDougal et al., 2003). Among
methicillin-resistant isolates, 4 were classified as USA100 (92325,
92450, 94246, 94654), 3 as USA300 (95689, 97635, 98833), and 2 as
USA1000 (100547, 100553). Among methicillin-susceptible isolates, 2
were classified as USA900 (92965, 98482) and the other 2 were deter-
mined to be non-USA100-1100 strains. Variability of strain type was
not observed between first and last isolate for all 7 patients. Each pa-
tient’s isolates were one strain type that was distinguishable from the
strain types identified in the other patients.
WGS was used to characterize genetic patterns of daptomycin resis-
tance in the first and last isolates of each patient, as shown in Table 2. In
all 7 patients, there was no change in genetic composition between the
first and last isolates. vraR, vraS, mprF, dltA, and cls2 were present in all
isolates independent ofmethicillin or daptomycin susceptibilities. How-
ever, the presence of gdpD was more selective. gdpD was not seen in
isolates that were methicillin-susceptible (4/13) and among the 8 iso-
lates classified as daptomycin non-susceptible, gdpD was present in 6
of 8 isolates.
3. Discussion
The results of this study are in accordance with recent literature
supporting synergistic combinations of daptomycin or vancomycin with
ceftaroline for SA bacteremia. Werth and colleagues reported synergy
with the use of vancomycin and ceftaroline combination in methicillin-
resistant vancomycin-intermediate SA isolates. They compared this
combination to vancomycin and oxacillin and found the ceftaroline com-
bination to be much more active, noting synergy in all but one strain
(Werth et al., 2013). Likewise, Barber and colleagues reported a similar
phenomenon seen in a single patient with daptomycin-non-susceptible
MRSA bacteremia. In vitro TKE revealed synergy with the use of
ceftaroline in combination with daptomycin or vancomycin compared
to any agent alone. Of note, the vancomycin and ceftaroline combination
showed greater killing compared to the combination of daptomycin and
ceftaroline. The teamalso reported a successful clinical outcomeof the pa-
tient with clearance of blood cultures after switching to the vancomycin
and ceftaroline combination (Barber et al., 2015).
Table 1
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Within our study cohort, patients 4-7 demonstrated synergy with
vancomycin plus ceftaroline at 0.5 ×MIC, while patients 4 and 6 isolates
also had synergy to daptomycin plus ceftaroline at 0.5 × MIC. Patient
four received six weeks of vancomycin plus ceftaroline, had recurrence
of bacteremia and was retreated with ceftaroline for 6 weeks followed
by doxycycline suppression as new hardware had been placed. Patient
five was treated with daptomycin 6 mg/kg daily alone, prior to dapto
MICs being reported, and expired. Patient 6 was treated initially with
daptomycin plus ceftaroline for 2 weeks followed by an 8 week course
of vancomycin and survived. Patient 7 was at an outside facility for
four weeks prior to transfer had had persistently positive blood cultures
in the setting of prosthetic aortic valve endocarditis complicated by aor-
tic root abscess. The patient received combinations of vancomycin with
gentamicin followed by daptomycin with gentamicin. He expired at our
facility after two days of therapy with daptomycin, gentamicin, and ri-
fampin. Patients 1–3 did not demonstrate synergy at 0.5 ×MIC to either
combination of antibiotics but did at 0.75 × MIC with vancomycin plus
ceftaroline (all patients) and daptomycin plus ceftaroline (patients 2
and 3). Patients 1 and 3 expired. Patient 1 was treated with daptomycin
10mg/kg plus ceftaroline and had clearance of the bacteremia. It re-
curred severalmonths later in which the isolate was susceptible to dap-
tomycin. The patient enrolled in hospice due to worsening heart and
renal failure and expired. Patient 3 was initially treated with vancomy-
cin in the setting of bacteremia and lumbar osteomyelitis. The patient
had a recurrence and was briefly treated with high dose daptomycin
plus linezolid followed by vancomycin plus linezolid. His infection re-
curred several years later. Patient 2 survived and was treated with a
course of ceftaroline.
Fig. 2. PFGE dendrogram comparing first and last isolates obtained from seven patients and digestedwith SmaI against established CDCMRSA strains 100-1100. Brackets distinguish each
set of patient isolates.
Table 2
Daptomycin resistance genes infirst and last S. aureus isolates as determined byWGS. The exception is Patient 7, whohad only one isolate collected to patient death before the collection of
a second isolate. Determination of daptomycin susceptibility was based on the CLSI breakpoint of N1 μg/mL (S = susceptible, NS = non-susceptible).
Patient Isolates Methicillin resistance status Daptomycin susceptibility status vraR vraS mprF dltA cls2 gdpD
1 92965 MSSA S + + + + +
98482 MSSA NS + + + + +
2 97635 MRSA S + + + + + +
98833 MRSA NS + + + + + +
3 97840 MSSA S + + + + +
98412 MSSA NS + + + + +
4 100547 MRSA NS + + + + + +
100553 MRSA NS + + + + + +
5 92325 MRSA S + + + + + +
92450 MRSA NS + + + + + +
6 94296 MRSA S + + + + + +
94654 MRSA NS + + + + + +
7 95689 MRSA NS + + + + + +
Control ATCC29213 MSSA - + + + + +
Control FoxR MRSA - + + + + + +
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Our studypopulationwas unique as all patients had at least one dap-
tomycin non-susceptible SA isolate obtained during inpatient treat-
ment, and 2 patients also had methicillin-susceptible strains. While
our findings agree with recent synergy literature, some interesting
trends were also noted in our study that warrant further investigation.
No isolate had synergy at 0.25 × MIC for either combination but in-
creasing concentrations to 0.5 × MIC led to synergy in the majority of
the vancomycin and ceftaroline studies,whichwasnot seenwithdapto-
mycin plus ceftaroline. Further increasing theMIC concentration to 0.75
×MIC led to synergy in all patientswith vancomycin and ceftaroline and
all but one patient in the daptomycin and ceftaroline studies. Since the
majority of the daptomycin and ceftaroline studies did not have synergy
below 0.75 ×MIC, higher daptomycin doses may be required in clinical
practice to eradicate SA infections. In recent literature, higher daptomy-
cin doses have been associated with improved mortality for SA bacter-
emia (Timbrook et al., 2018). Furthermore, in a review of salvage
therapy for persistent SA bacteremia by Sakoulas and colleagues, the
combination of ceftaroline and daptomycin, most commonly dosed at
8–10mg/kg, was successful for 25 out of 26 patients receiving that com-
bination (Sakoulas et al., 2014).
Another interesting phenomenon observed in our studywas that syn-
ergy was more likely to be observed at lower MIC concentrations if the
vancomycin or daptomycin MIC was elevated. For example, patient
four’s first staphylococcal isolate with a daptomycin MIC of 0.5 μg/mL
did not have synergy observed at any MIC concentration for daptomycin
and ceftaroline, but the patient’s last isolate with a daptomycinMIC of 16
μg/mL had daptomycin and ceftaroline synergy observed at 0.5 × MIC.
This was also seen in patients one through three for the vancomycin
plus ceftaroline combination and patients 5 and 6 for the daptomycin
plus ceftaroline combination. The reasoning behind this phenomenon
may be explained by one of the resistancemechanisms of SA.These bacte-
ria have developed many different mechanisms of resistance, including
synthesis of PBP2a which replaces other PBPs and limits all beta-lactam
binding, as seen in MRSA. It can also alter peptidoglycan synthesis that
leads to thickened cell walls and resistance to vancomycin (Lowy,
2003). Daptomycin resistance may result from cell membrane changes,
including modification of a negative charge to a more positive charge, in-
creased rigidity or fluidity of themembrane, or reduction of the phospho-
lipid head groups phosphotidylglycerol and cardiolipin (Bayer et al.,
2014). Any combination of these resistance mechanisms can produce re-
sistance to an antimicrobial, but leave other antimicrobials susceptible or
more susceptible depending on themechanismof action of the antimicro-
bial.Mutations leading to changes in the cellwallwhich raise vancomycin
and/or daptomycin MICs could lead the organism to be more susceptible
to synergy when these antimicrobials are combined with ceftaroline or
any other beta-lactam, also known as the “seesaw effect”.
There are limitations to the current study. Our study was completed
in a small sample of 13 isolates of seven patients that were all treated at
the same institution, which cannot be generalized to all daptomycin
non-susceptible isolates. These synergy tests were only completed in
daptomycin non-susceptible strains, and the results cannot be applied
to daptomycin susceptible strains. Synergy testing was completed
with ceftaroline plus vancomycin or daptomycin, but no other antimi-
crobials, which leads to further questions about other agents to use in
combination that may have synergistic relationships. Furthermore, our
in vitro synergy data does not necessarily translate to in vivo synergy
outcomes, whichmust be evaluated in larger patient populations to de-
termine themost appropriate therapy for these patients. In vitro exper-
iments depend on laboratory technician judgement and technique,
which may lead to errors in interpretation, although our duplicate ex-
periments did not differ in synergy results.
Our study highlights the importance of further investigation into dif-
ferences in SA strain types, as genomic sequencingmay reveal genes asso-
ciated with antimicrobial combination therapy success or failure. Our
laboratory investigated these patients’ SA isolates using pulse field gel
electrophoresis and found that changes in daptomycin susceptibility
werewithin one strain typewithoutmodification or introduction of addi-
tional strain types.
In the absence of additional strain types ormodification of strain type,
as determinedby PFGE, it can be ascertained that for this groupof isolates,
the development of daptomycin non-susceptibility is due to intrinsic
changes. The presence of cell envelope modification genes vraS, vraR,
dltA, mprF and cls2 in both daptomycin-susceptible and daptomycin-
non-susceptible isolates indicates the possibility of gene upregulation in
the setting of prolonged antibiotic treatment. This has been previously
demonstrated with vraSR and mprF (Mehta et al., 2012), as well as, dltA
(Cafiso et al., 2014). Further investigation is needed to pinpointmutations
in these loci between first and last isolates that could have contributed to
the development of daptomycin resistance.
Additionally, gdpD was only seen in MRSA isolates and was isolated
in 6 of 8 daptomycin non-susceptible strains, suggesting an association
of gene expressionwithmethicillin status and its contribution to the de-
velopment of daptomycin resistance (Sundaram et al., 2018).
This study also highlights the need for animalmodels to evaluate the
effect of daptomycin dosing on synergy with ceftaroline for SA bacter-
emia. Investigating further into SA resistance and treatment options
will allow us to better understand the most appropriate management
of these difficult to treat infections.
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